Evaluation of a new antituberculous agent. Rifampin (Rifadin, Rimactane).
D000284:Administration, Oral; D002353:Carrier State / Q000517:prevention & control; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D009164:Mycobacterium Infections / Q000188:drug therapy*; D009345:Neisseria meningitidis / Q000187:drug effects; D011247:Pregnancy; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy*
D012293:Rifampin